• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women suffering from ADHD face a difficult decision about whether to continue or stop taking ADHD medication during pregnancy and breastfeeding. There isn't much information on how long-term exposure to these medications could affect the fetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological disorders such as impaired hearing or vision, febrile seizures or IQ impairment. The authors acknowledge the need for higher-quality research.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medications must weigh the advantages of using them against the risks to the fetus. Physicians don't have the data to give clear advice, but can provide information on the risks and benefits to assist pregnant women to make an informed decision.

A study published in Molecular Psychiatry found that women who took adhd medication pregnancy (Read More Listed here) medications during early pregnancy did not have a significantly increased risk of fetal heart malformations or major structural birth defects. Researchers conducted a large sample-based case control study to compare the incidence of major structural defects in infants born to mothers who took stimulants during pregnancy. Clinical geneticists, pediatric cardiologists and other experts reviewed the cases in order to ensure that the classification was correct and to minimize any bias.

However, the study was not without its flaws. The most important issue was that they were unable to distinguish the effects of the medication from the underlying disorder. This limitation makes it difficult to determine whether the small associations observed in the groups that were exposed result from medication use or confounding by comorbidities. In addition the study did not examine long-term offspring outcomes.

The study revealed that infants whose mother had taken ADHD medication during pregnancy had a higher chance of being admitted to the neonatal care unit (NICU), compared to those whose mothers did not take any medication during pregnancy or discontinued taking their medication prior to or during pregnancy. This was due to central nervous system-related disorders and the increased risk for admission was not found to be influenced by which stimulant medications were taken during pregnancy.

Women who were taking stimulant ADHD medications during pregnancy also had a higher likelihood of having to have a caesarean section or one whose baby scored low on the Apgar scale (less than 7). These risks did not seem to be influenced by the type of medication that was used during pregnancy.

Researchers suggest that the small risks posed by the use of ADHD medications during early pregnancies can be offset by greater benefits to both mother and baby from continuing treatment for the woman's condition. Physicians should talk to their patients about this and try to help them develop coping strategies that could reduce the impact of her disorder in her daily life and relationships.

Medication Interactions

Many doctors prescribing adhd medication are faced with the decision of whether to maintain treatment or stop it during pregnancy as more women are diagnosed with ADHD. These decisions are frequently made without clear and authoritative evidence. Instead, physicians must consider their own expertise, the experience of other physicians and the research on the topic.

Particularly, the subject of potential risks for the baby can be tricky. The research that has been conducted on this topic is based on observations rather than controlled studies, and a lot of the results are in conflict. The majority of studies limit their analysis to live-births, which could underestimate the severity of teratogenic effects leading to terminations or abortions of pregnancy. The study presented in the journal club addresses these shortcomings, by examining both information on deceased and live births.

The conclusion is that while certain studies have demonstrated that there is a positive correlation between ADHD medications and the risk of certain birth defects, other studies have found no connection and the majority of studies have a neutral or slightly negative impact. In all cases an in-depth evaluation of the risks and benefits is required.

For a lot of women with ADHD, the decision to stop medication is difficult, if not impossible. In a recent piece published in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can increase depression and feelings of being isolated. In addition, a decrease in medication may affect the ability to perform jobs and drive safely that are crucial aspects of a normal life for many people suffering from ADHD.

She suggests women who are unsure about whether to continue or stop taking medication because of their pregnancy consider informing family members, friends, and coworkers on the condition, its impact on daily functioning, and the advantages of staying on the current treatment regimen. It can also make the woman feel more comfortable as she struggles with her decision. It is important to remember that certain medications are able to pass through the placenta, so if a woman decides to stop her ADHD medication during pregnancy and breastfeeding, she should be aware that the effects of the drug could be transferred to the infant.

Risk of Birth Defects

As the use and use of ADHD medications to treat the symptoms of attention deficit hyperactivity disorder (adhd medication list), increases, so does concern about the possible effects of the drugs on foetuses. A study that was published in the journal Molecular Psychiatry adds to the existing information on this topic. Researchers used two massive datasets to analyze over the counter adhd medication uk 4.3 million pregnancies and determine whether stimulant medications increased the risk of birth defects. Researchers found that while the overall risk is low, the first trimester ADHD exposure to medication was associated with slightly higher risk of specific heart defects like ventriculoseptal defect.

The authors of the study did not discover any link between early medication usage and other congenital anomalies, such as facial deformities or club feet. The results are in the same vein as previous studies that showed a small, but significant increase in the number of cardiac malformations among women who began taking ADHD medication before pregnancy. This risk increased during the latter part of pregnancy, when a lot of women began to stop taking their medication.

Women who were taking ADHD medication during the first trimester were more likely require a caesarean birth, have a low Apgar after birth and have a baby who needed breathing assistance at birth. However the researchers of the study were unable to eliminate selection bias by restricting the study to women who didn't have any other medical conditions that could have contributed to these findings.

The researchers hope their study will help inform the clinical decisions of physicians who treat pregnant women. They advise that while a discussion of the risks and benefits is crucial however, the decision to stop or continue treatment must be based on each woman's needs and the severity of her ADHD symptoms.

The authors warn that, even though stopping the medication is an option to look into, it is not recommended because of the high incidence of depression and other mental problems among women who are pregnant or recently gave birth. Further, research shows that women who stop taking their medications will have a difficult transitioning to life without them after the baby is born.

Nursing

It can be a stressful experience to become a mom. Women who suffer from ADHD who have to deal with their symptoms while attending doctor appointments, getting ready for the arrival of their child and adjusting to new adhd medication uk household routines can experience severe challenges. This is why many women decide to continue taking their ADHD medications throughout the course of pregnancy.

The majority of stimulant medications are absorbed through breast milk in very small amounts, so the risk for breastfeeding infant is minimal. However, the amount of medication exposure to the infant can differ based on dosage, frequency it is administered and at what time it is administered. In addition, individual medications enter the baby's system differently through the gastrointestinal tract and breast milk. The impact of this on a newborn infant is not well known.

Due to the absence of research, some physicians may recommend stopping stimulant medications during a woman's pregnancy. This is a difficult decision for the woman, who must weigh the benefits of her medication against the risks to the embryo. In the meantime, until more information is available, doctors prescribing adhd medication may inquire about pregnant patients if they have an background of ADHD or if they plan to take medication in the perinatal stage.

Numerous studies have demonstrated that women can continue to take their ADHD medication without risk during pregnancy and breast-feeding. In response, a rising number of patients are opting to do so. They have found, in consultation with their physicians, that the benefits of continuing their current medication far outweigh any potential risks.

Women who suffer from ADHD who are planning to breastfeed should seek advice from a specialist psychiatrist before becoming pregnant. They should discuss their medication with their prescriber and discuss the advantages and adhd medication pregnancy disadvantages of continuing treatment, including non-pharmacological strategies. Psychoeducation is also required to help pregnant people with ADHD understand their symptoms and the root cause and learn about treatment options and strengthen existing strategies for managing. This should be a multidisciplinary approach including obstetricians, GPs and psychiatry. Pregnancy counseling should include a discussion of a treatment plan for the mother as well as the child, monitoring of signs of deterioration and, if necessary, adjustments to the medication regimen.